Back to search results

Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Conditions

Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Karmanos Cancer Institute, Detroit, Michigan, United States

    Contact: Study coordinator (Christiane Houde) · Houdec@karmanos.org · 3135768673
    Contact: Principal Investigator (Jeffrey Zonder, M.D.)
    Suresh Balasubramanian, M.D. (Sub-investigator)
    Abhinav Deol, M.D. (Sub-investigator)
    Indryas L Woldie, M.D. (Sub-investigator)
    Andrew Kin, M.D. (Sub-investigator)
    Dipenkumar Modi, M.D. (Sub-investigator)
    Lois Ayash, M.D. (Sub-investigator)
    Melissa Runge Morris, M.D. (Sub-investigator)
    Vijendra Singh, M.D. (Sub-investigator)
    Joesph Uberti, M.D. PhD (Sub-investigator)
    Jay Yang, M.D. (Sub-investigator)
    Craig Cole, M.D. (Sub-investigator)

  • KCI at McLaren Greater Lansing, Lansing, Michigan, United States

    Contact: Study coordinator (Craig Cole, M.D.) · colec@karmanos.org · 734-664-2488
    Craig Cole, M.D. (Sub-investigator)
Study leads

  • Jeffrey Zonder, M.D.

    Principal Investigator

    Barbara Ann Karmanos Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)